<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018758</url>
  </required_header>
  <id_info>
    <org_study_id>NHLPal</org_study_id>
    <nct_id>NCT01018758</nct_id>
  </id_info>
  <brief_title>Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy</brief_title>
  <acronym>NHLPal</acronym>
  <official_title>Phase II Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin&#xD;
      Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified&#xD;
      Hesketh classification for antiemetic therapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall rate of patients achieving a complete response (defined as no emetic episode and no use of rescue medication)</measure>
    <time_frame>0-120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of Complete Response</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of emetic episodes</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of nausea graded according to Likert scale</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure (first emetic episode or first need of rescue medication, whichever occurs first)</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient global satisfaction with antiemetic therapy, as measured by a visual analog scale (VAS)</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxic effects of Palonosetron</measure>
    <time_frame>within the first 24 h after chemotherapy and 24-120 h</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <condition>Non Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.</description>
    <arm_group_label>palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, &gt;18 years of age;&#xD;
&#xD;
          -  Histologically or cytologically confirmed aggressive NHL (any stage in accordance with&#xD;
             the REAL Classification);&#xD;
&#xD;
          -  Patients candidates to a initial chemotherapy treatment;&#xD;
&#xD;
          -  ECOG performance status of 0-1;&#xD;
&#xD;
          -  Scheduled to receive a single intravenous dose of at least one of the moderately&#xD;
             emetogenic agents (according to the modified Hesketh classification) on Day 1;&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Female of childbearing potential must be using reliable contraceptive measures;&#xD;
&#xD;
          -  Acceptable hepatic and renal functions;&#xD;
&#xD;
          -  Willing and able to complete the patient diary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Highly emetogenic chemotherapy (containing cisplatin, mechlorethamine, streptozotocin,&#xD;
             cyclophosphamide &gt;1500 mg/sqm; carmustine; dacarbazine; hexamethylmelamine;&#xD;
             procarbazine), or single-agent chemotherapy with drugs having low/minimal emetogenic&#xD;
             potential according to the Hesketh classification);&#xD;
&#xD;
          -  Diagnosis of Hodgkin's Disease or Leukemia;&#xD;
&#xD;
          -  Candidates to High-Dose Chemotherapy or Bone Marrow/Peripheral Blood Stem Cells&#xD;
             Transplantation;&#xD;
&#xD;
          -  Chemotherapy schedules considering the administration of emetogenic drugs in more than&#xD;
             two consecutive days;&#xD;
&#xD;
          -  Have received any investigational drugs within 30 days before study entry;&#xD;
&#xD;
          -  Have received any drug with potential anti-emetic efficacy (with the exception of&#xD;
             specific corticosteroids foreseen in the chemotherapy combination) within 24 hours of&#xD;
             treatment initiation);&#xD;
&#xD;
          -  Prior treatment with Palonosetron;&#xD;
&#xD;
          -  Have a seizure disorder requiring anticonvulsant medication unless clinically stable&#xD;
             and free of seizure activity;&#xD;
&#xD;
          -  Experienced or ongoing vomiting or nausea from any organic etiology, in the screening&#xD;
             phase;&#xD;
&#xD;
          -  Clinical evidence of current or impending bowel obstruction, peritonitis, infection,&#xD;
             uremia, severe mucositis;&#xD;
&#xD;
          -  Clinically relevant electrolyte abnormalities;&#xD;
&#xD;
          -  Have a known hypersensitivity to 5HT3 receptor antagonists;&#xD;
&#xD;
          -  Radiotherapy within 30 days before chemotherapy administration, or scheduled to&#xD;
             receive radiotherapy within two weeks after chemotherapy;&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding;&#xD;
&#xD;
          -  Inability to understand or cooperate with the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Di Renzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Italiano Studio Linfomi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gruppo Italiano Studio Linfomi</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>November 24, 2009</last_update_submitted>
  <last_update_submitted_qc>November 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nicola Di Renzo</name_title>
    <organization>Gruppo Italiano Studio Linfomi</organization>
  </responsible_party>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Chemotherapy toxicity</keyword>
  <keyword>aggressive Non Hodgkin's Lymphomas treated with moderately emetogenic chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

